{"product_id":"irtc-marketing-mix","title":"(IRTC) iRhythm Technologies, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis iRhythm Technologies, Inc. 4P's Marketing Mix Analysis explains the company’s product offering, pricing approach, distribution channels, and promotion tactics in a concise, actionable format. The page shows a genuine preview\/sample of the analysis so you can review style and content; purchase the full version to obtain the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZio service, ambulatory ECG monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZio is iRhythm Technologies, Inc.'s core ambulatory ECG service, using a 14-day patch to record heart rhythm data outside the hospital. It helps physicians spot arrhythmias in patients at risk of heart rhythm disorders in the U.S. The service is built for high-yield detection, with one patch worn continuously for up to 14 days.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZio XT, up to 14-day wearable patch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZio XT is a single-use, patch-based wireless biosensor that records every heartbeat and ECG signal for up to 14 days, giving iRhythm Technologies, Inc. a clear edge over a standard office ECG that captures only a few minutes. The longer wear window helps catch intermittent arrhythmias that short tests often miss. In 2025\/2026, that extended monitoring stayed central to demand for outpatient cardiac diagnostics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZio AT, mobile cardiac telemetry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZio AT combines a patch form with mobile cardiac telemetry, so patients can wear it for up to 14 days while heart data is sent near real time. It helps clinicians watch rhythm events sooner than delayed Holter review, and it is built for patients who need closer oversight. In iRhythm Technologies, Inc. terms, it sits in the high-need monitoring segment where earlier detection can change care paths.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCloud analysis platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. uses a cloud analysis platform to turn patch-based ECG data into physician-ready reports, so the hardware and software work as one service. This is central to the Company Name model because the patch captures the signal, and the cloud platform cleans, analyzes, and packages it for clinical review. The value is speed, scale, and lower manual review burden.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatch data goes straight to the cloud.\u003c\/li\u003e\n\u003cli\u003eECG data becomes readable reports.\u003c\/li\u003e\n\u003cli\u003eHardware and software drive one workflow.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVerily partnership, future AF screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. works with Verily Life Sciences LLC on atrial fibrillation screening, detection, and monitoring, which could broaden its reach beyond Zio. AF affects about 33.5 million people worldwide, so the addressable need is large and recurring.\u003c\/p\u003e\n\u003cp\u003eThe tie-up fits product growth by adding algorithm-led screening to iRhythm's patch-based monitoring base, and it may support future launch options in preventive heart care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAF market: very large, underdiagnosed\u003c\/li\u003e\n\u003cli\u003eVerily adds screening R\u0026amp;D depth\u003c\/li\u003e\n\u003cli\u003eCould extend beyond Zio\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eiRhythm's Zio platform: smarter long-wear ECG for hidden heart rhythms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. sells Zio as its core product: a 14-day patch ECG service that helps find intermittent arrhythmias outside the clinic. Zio XT and Zio AT extend that platform with longer wear and near real-time review, while cloud analysis turns raw signals into physician-ready reports. The Verily tie-up adds AF screening potential in a very large need area.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003eWear\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZio\u003c\/td\u003e\n\u003ctd\u003eAmbulatory ECG\u003c\/td\u003e\n\u003ctd\u003e14 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZio AT\u003c\/td\u003e\n\u003ctd\u003eMobile telemetry\u003c\/td\u003e\n\u003ctd\u003e14 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConcise, company-specific 4P analysis of iRhythm Technologies, Inc. covering Product, Price, Place, and Promotion with real-world market context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eSummarizes iRhythm’s 4Ps in a simple, at-a-glance format that helps teams quickly spot strategic gaps and align on action.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources (industry reports, FDA filings, and peer-reviewed studies) to fast-verify iRhythm market, pricing, and competitive claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S.-focused market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. sells mainly in the U.S., so its market access is tied to U.S. hospitals, physicians, and payer workflows. In FY2024, revenue was about $587 million, and U.S. cardiac rhythm care remained its core demand base. That domestic focus lets iRhythm align Zio services with U.S. diagnostic and reimbursement paths.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect sales to physicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. sells Zio through cardiologists, electrophysiologists, and referring physicians, not retail stores, so the product stays inside clinical decision-making. That channel fit helped support 2024 net revenue of about $559 million, with ordering driven by 3 million+ patients monitored over time. The model keeps Zio embedded in care pathways and physician workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth-system and clinic channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospitals and outpatient clinics are the main order points for iRhythm Technologies, Inc.'s Zio monitoring, especially when clinicians suspect arrhythmias. The channel fits repeat use across care networks, since one patient can move from emergency care to outpatient follow-up under the same referral path. iRhythm Technologies, Inc.'s 2025 filings show a growing installed base and expanding clinician adoption across these settings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eShip-to-patient workflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. uses a ship-to-patient model for the Zio patch, sending the wearable directly to the patient for at-home wear, then routing the device and ECG data back to iRhythm’s processing system. This lowers friction versus in-clinic setup and reduces the need for repeated in-person monitoring visits. \u003c\/p\u003e\n\u003cp\u003eThis model fits telehealth-style care: one device, one shipment, and continuous data capture during the wear period. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHome delivery cuts clinic dependence\u003c\/li\u003e\n\u003cli\u003eReturned data feeds central analysis\u003c\/li\u003e\n\u003cli\u003eSupports remote cardiac monitoring\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCloud-delivered results\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. delivers Zio results through a cloud platform, so clinicians get interpreted ECG reports electronically wherever they practice. The model supports remote review across the full 14-day wear period and helps speed decisions without tying care to one site.\u003c\/p\u003e\n\u003cp\u003eIn 2025, this digital workflow backed a business that served hundreds of thousands of patients and generated more than $500 million in annual revenue, showing the scale of cloud-based delivery.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCloud review cuts location limits.\u003c\/li\u003e\n\u003cli\u003eECG reports arrive electronically.\u003c\/li\u003e\n\u003cli\u003e14-day wear supports broader monitoring.\u003c\/li\u003e\n\u003cli\u003e2025 revenue topped $500 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eiRhythm’s U.S.-First Patch Model Powers Cloud-Reviewed ECG Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. uses a U.S.-first place model: physicians order Zio, the patch ships to patients, and results return through cloud review. That fits hospital and outpatient workflows and keeps care inside U.S. reimbursement paths. FY2024 revenue was about $587 million, showing the scale of this channel-led delivery.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace\u003c\/th\u003e\n\u003cth\u003eModel\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003eCore market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShip-to-patient\u003c\/td\u003e\n\u003ctd\u003eHome wear\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCloud\u003c\/td\u003e\n\u003ctd\u003eECG reports\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eiRhythm Technologies, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual document you’ll receive instantly after purchase—no surprises. This iRhythm Technologies 4P’s Marketing Mix analysis is complete, editable, and ready to use, covering product, price, place, and promotion with actionable insights and data-driven recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical utility messaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. promotes clinical utility by showing that continuous ECG monitoring can detect arrhythmias missed by short Holter tests, with Zio used for up to 14 days. The message targets clinicians managing cardiac rhythm patients and stresses clearer diagnostic insight, faster decisions, and better care pathways. This works because the value is clinical first: more monitored time means a higher chance of catching real events.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. sells physician education directly to doctors and care teams, which fits a channel-led model where the product is ordered through medical workflows. Its outreach teaches patient selection and how to fit Zio’s workflow into clinic routines, helping reduce ordering friction. The Zio monitor can record cardiac data for up to 14 days, so clear training matters for correct use and follow-through.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical evidence and publications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. promotes Zio with clinical evidence, not broad brand claims; that fits medtech, where published outcomes drive adoption. Its monitor records up to 14 days of continuous ECG data, which helps show more arrhythmias than 24- to 48-hour Holter monitoring. That longer wear time and peer-reviewed data help set it apart from shorter-duration options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eConferences and KOL outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. uses cardiology and electrophysiology conferences to reach the right prescribers fast, and KOL outreach helps turn peer trust into adoption. This is standard medtech promotion: specialist meetings bring concentrated reach, while expert voices can support credibility for products used in arrhythmia monitoring.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets high-value specialist buyers\u003c\/li\u003e\n\u003cli\u003eBuilds trust through KOL validation\u003c\/li\u003e\n\u003cli\u003eFits normal healthcare tech promotion\u003c\/li\u003e\n\u003cli\u003eBest for clinical education and adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership and press communications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. uses partnership news, like its Verily tie-up, to frame promotion around innovation in atrial fibrillation care. Corporate updates help keep the growth story visible and show the company’s push beyond its core Zio monitoring base. This matters in a market where AF affects about 59 million people worldwide, so future care capability is a strong signal.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVerily = innovation-led promotion\u003c\/li\u003e\n\u003cli\u003eAnnouncements support growth messaging\u003c\/li\u003e\n\u003cli\u003eAF scale strengthens the story\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eiRhythm’s Zio: Longer ECG Monitoring, Smarter Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. promotes Zio through clinician education, KOL support, and conference outreach, all aimed at cardiologists and electrophysiologists. Its core message is simple: up to 14 days of continuous ECG can find arrhythmias missed by 24 to 48 hour Holters. With 2025 revenue at $648.8 million, promotion is tied to growth, not brand noise.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZio wear time\u003c\/td\u003e\n\u003ctd\u003eUp to 14 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue\u003c\/td\u003e\n\u003ctd\u003e$648.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore buyers\u003c\/td\u003e\n\u003ctd\u003eCardiology, EP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo public retail list price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. does not sell Zio like a retail device, so there is no public shelf price. The service is ordered by healthcare providers and billed through medical channels, which makes contract and reimbursement terms more important than list price. In 2025, iRhythm reported revenue of about $580 million, showing the model is driven by clinical use, not consumer pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance-reimbursed diagnostic service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. prices its cardiac monitoring service through reimbursement, not direct patient payment, so commercial insurers and government programs drive revenue. That model fits diagnostic services like Zio, where payer coverage and coding decide adoption. In 2025, this meant contract wins and CMS coverage mattered more than list price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePer-patient billing model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. uses a per-patient billing model, so each monitoring episode turns into diagnostic revenue. In 2024, revenue was $498.2 million and the company reported 1.2 million Zio monitor reports, showing how price tracks clinical use. That makes pricing less about a fixed device sale and more about how often doctors order monitoring.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eContracted payer pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. prices its service through payer contracts and coverage terms, so the realized price can differ by account. Hospitals and physician groups usually buy it under negotiated medical billing arrangements, which makes net revenue per test depend on the payer mix and the contract terms in force in FY2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrice varies by payer contract\u003c\/li\u003e\n\u003cli\u003eCoverage terms shape reimbursement\u003c\/li\u003e\n\u003cli\u003eRealized price is account-specific\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eValue-based diagnostic economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. prices around clinical value, not just device cost: its Zio service offers up to 14 days of continuous ECG monitoring, which helps find intermittent arrhythmias that short tests can miss. That longer wear time can cut repeat testing and support premium reimbursement, especially as arrhythmia burden keeps rising in older adults and high-risk patients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrices track diagnostic value, not hardware\u003c\/li\u003e\n\u003cli\u003e14-day monitoring lifts detection yield\u003c\/li\u003e\n\u003cli\u003eFewer repeats can lower downstream costs\u003c\/li\u003e\n\u003cli\u003eSupports premium reimbursement positioning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eiRhythm’s Revenue Rises on Reimbursement-Driven Zio Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eiRhythm Technologies, Inc. prices Zio through payer reimbursement, so the realized rate depends on coverage, coding, and contract terms rather than a public list price. FY2025 revenue was about $580 million, up from $498.2 million in FY2024, showing pricing is tied to testing volume and payer mix. The 14-day monitor supports value-based reimbursement.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue: $580 million\u003c\/td\u003e\n\u003ctd\u003eRevenue: $498.2 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eModel: reimbursement-based\u003c\/td\u003e\n\u003ctd\u003eModel: reimbursement-based\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234577129737,"sku":"irtc-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/irtc-marketing-mix.webp?v=1785722362","url":"https:\/\/dcfanalyst.com\/products\/irtc-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}